State Street's stake is below the 5% threshold, so no further 13G amendments are required unless it crosses back above 5%. Monitor for any future 13D conversion or material changes in institutional ownership.
CTMX drugs
CTMX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.98entry
- T+1 · 6d ago +7.58%α +6.26% · $2.13
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp filed a Schedule 13G disclosing a passive 4.1% stake in CytomX Therapeutics as of September 30, 2026, down from the 5.0%+ threshold that would require a 13G filing. The filing is a routine passive ownership update with no activist intent.
Key Financial Metrics
Key Facts
- State Street Corp disclosed beneficial ownership of 9,025,855 shares of CytomX Therapeutics common stock as of September 30, 2026.
- The stake represents 4.1% of shares outstanding, below the 5% threshold that would trigger a 13G filing requirement.
- State Street certifies the securities were acquired and held in the ordinary course of business with no intent to influence control.
- This is a new Schedule 13G filing (not an amendment) for State Street, which previously filed an initial 13G on August 7, 2026.
Financial Impact
State Street holds 9,025,855 shares, approximately 4.1% of CTMX outstanding shares, valued at roughly $19.5M based on the $477M market cap.
Risk Factors
- State Street's stake is passive and below 5%, indicating reduced institutional conviction compared to the prior 5.4% stake held by Bank of America.
- No activist intent is signaled; the filing is purely administrative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000642 |
| Document: 0000093751-26-000642-index.html | 0000093751-26-000642 |
| Document: 0000093751-26-000642.txt | 0000093751-26-000642 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Viewing Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers